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ABSTRACT
Human papillomavirus (HPV) can successfully evade the host immune response to establish a persistent infection. We show
here that expression of the E7 oncoprotein in primary human keratinocytes results in increased production of interleukin-18
(IL-18) binding protein (IL-18BP). This anti-inflammatory protein is a natural antagonist of IL-18 and is necessary for skin ho-
meostasis. Wemap increased IL-18BP production to the CR3 region of E7 and demonstrate that this ability is shared among E7
proteins from different HPV types. Furthermore, mutagenesis shows that increased IL-18BP production is mediated by a gam-
ma-activated sequence (GAS) in the IL-18BP promoter. Importantly, the increased IL-18BP levels seen in E7-expressing kerati-
nocytes are capable of diminishing IL-18-mediated CD4 lymphocyte activation. This study provides the first evidence for a virus
protein that targets IL-18BP and further validates E7 as a key component of the HPV immune evasion armor.
IMPORTANCE
Infection with human papillomavirus is a leading cause of morbidity andmortality worldwide. This study demonstrates that the
E7 protein increases production of the anti-inflammatory IL-18BP, a major regulator of epithelial homeostasis. A number of E7
proteins can increase IL-18BP production, and a region within the CR3 of E7 is necessary for mediating the increase. A conse-
quence of increased IL-18BP production is a reduction in CD4-positive lymphocyte activation in response to IL-18 costimula-
tion. These findings may shed light on the immune evasion abilities of HPV.
Human papillomaviruses (HPVs) are small double-strandedDNA (dsDNA) viruses that infect squamous epithelial cells
and produce a range of clinical lesions ranging from common
warts to cancers of the anogenital tract and oropharynx. More
than 100 types have been identified (1) and are classified as either
low- or high-risk types, depending on the associated risk of cancer
development. High-risk HPVs are responsible for the majority of
cervical cancers and a subset of head and neck squamous cell car-
cinomas (2), and among these, HPV16 is detected in approxi-
mately 60% of all cervical cancers worldwide (3). Carcinogenesis
is linked to persistent infection with a high-risk HPV type that
may last several years. This suggests that HPVs have evolved
mechanisms to evade the immune system.
Three virus-encoded proteins, E5, E6, and E7, have been
shown to impact the host’s ability to mount an effective immune
response. Although little is known about the E5 protein, which is a
minor oncoprotein, it has been correlated with decreased cell sur-
face expression ofmajor histocompatibility complex (MHC)mol-
ecules and reduced activation of the adaptive immune response
(4, 5). A significant number of studies have demonstrated the
myriad of interactions between the E6 and E7 oncoproteins and
the host immune system. It has been shown that they cooperate to
downregulate expression of a number of inflammatory cytokines,
including interleukin-18 (IL-18) and IL-8, and the chemoattrac-
tants monocyte chemoattractant protein 1 (MCP-1) and MIP3
(6–9). Furthermore, they reduce the production of antiviral inter-
ferons by subverting the actions of interferon (IFN) regulatory
factors (IRFs) (10, 11) and nuclear factor kappa B (NF-B) (12,
13). More recently, they have been implicated in the reduced pro-
duction of type III IFNs (14).
Keratinocytes are the targets for infection by HPVs, and they
are capable of responding to awide array of pathogens by secreting
cytokines to attract and activate the innate and adaptive immune
responses (15), in particular interleukin-18 (IL-18), which is a
proinflammatory cytokine that plays a protective role against vi-
rus infection by regulating the secretion of gamma interferon
(IFN-) from TH1 lymphocytes, enhancing the cytotoxicity of
natural killer (NK) cells (16), and bolstering the antiviral capacity
of keratinocytes (17, 18). The proinflammatory effects of IL-18 are
counterbalanced by a natural antagonist, IL-18 binding protein
(IL-18BP), which acts to suppress the deleterious effects of exces-
sive IL-18 secretion in vivo (19). Given the critical nature of the
IL-18–IL-18BP axis for regulating inflammatory responses of the
skin, it is likely to be a critical factor governing the persistence of
skin-tropic viruses. Indeed, poxviruses are known to encode func-
tional IL-18BP homologues, which contribute to virus virulence
by downregulating IL-18-mediated inflammatory responses (20).
Despite the body of evidence regarding the importance of IL-18BP
for regulating the epithelial inflammatory response, there is cur-
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rently no published observation of direct virus modulation of en-
dogenous IL-18BP.
This study shows that following stimulation with IFN-, pri-
mary human keratinocytes expressing E7 produce significantly
higher levels of IL-18BP than control cells. Using a panel of estab-
lishedmutants, the CR3 region of E7was found to be necessary for
increased IL-18BP production. The result of the increased IL-
18BP production was decreased CD4-positive lymphocyte activa-
tion. These results suggest that increased IL-18BPproductionmay
be a novel mechanism by which HPV could evade the immune
response and persist in the epithelium.
MATERIALS AND METHODS
DNAmanipulations.The plasmid pBabe-Puro was used to transiently or
stably express E6, E7, or E6/E7 products. Constructs containing E6, E7, or
E6/E7 from HPV6, -11, or -16 were provided by Dennis McCance
(Queen’sUniversity Belfast). TheHPV18E7 sequencewas amplified from
the full-length HPV18 genome, provided by Sally Roberts (University of
Birmingham), and ligated into pBabe-Puro using BamHI and EcoRI sites.
HPV16 E7 point and truncation mutants were obtained from Lawrence
Banks (ICGEB, Trieste, Italy). The IL-18BP luciferase reporter plasmids
have been described previously (21) and were provided by Heiko Muhl
(University of Frankfurt, Germany). DNA sequences of all inserts were
verified (GATC).
Cell culture. Primary human foreskin keratinocytes were obtained
from Sally Roberts and cultured as described previously (22). Cells were
cultured in SFM keratinocyte growthmedium (Invitrogen) containing 25
g/ml bovine pituitary extract and 0.1 ng/ml epidermal growth factor
(EGF). Cells were passaged for a maximum of 6 passages. NIH J2 3T3
fibroblasts (a gift from Sally Roberts) were cultured in Dulbeccomodified
Eagle medium (DMEM) containing 10% fetal bovine serum (FBS) and 2
mM L-glutamine.
Generation of stable keratinocyte lines containing the HPV18 ge-
nome. The HPV18-pGEMII plasmid (Sally Roberts, University of Bir-
mingham), containing the total HPV18 genome (accession number
NC_001357), was digested with EcoRI to release the genome, which was
then recircularized with T4 ligase (NEB). The genome was cotransfected
with a plasmid containing neomycin resistance into SFM keratinocyte
growth medium. The cells were selected with 100 g/ml G418 (Roche) E
medium containing 5% (vol/vol) serum, 2 mM L-glutamine, and 5 nM
EGF for 8 days. Cells were selected on a layer of J2 3T3 fibroblast feeders
(NIH) treated with 8 g/ml mitomycin C (Roche).
Retrovirus transduction. Stocks of retrovirus for transduction of pri-
mary cells were produced by transfection of the Phoenix packaging cell
line. Supernatants from transfected cells were added to target cells with 5
g/ml Polybrene at 37°C. Virus was removed from cells after 6 h of incu-
bation, and cells were fed fresh medium. After 48 h of recovery at 37°C,
cells were placed under selection in 5 g/ml puromycin.
Isolation of primary CD4 lymphocytes. Primary cells were extracted
and analyzed in accordance with the ethical rules of the University of
Hannover Medical School (3362) and the University of Leeds, Faculty of
Biological Sciences (BIOSCI09-001). To isolate peripheral blood mono-
nuclear cells (PBMCs), 30 to 60ml of peripheral blood was collected from
healthy donors in sterile Vacutainer lithium heparin (BD Biosciences,
Oxford, United Kingdom). Blood was kept at room temperature after
donation and used immediately. PBMCs were isolated from peripheral
whole blood using density gradients. Peripheral blood was diluted 1:1
with sterile phosphate-buffered saline (PBS) (Gibco, Life Technologies,
United Kingdom). An equal amount of diluted blood was then carefully
layered onto Ficoll-Paque Plus (GEHealthcare, Buckinghamshire, United
Kingdom). This was then centrifuged for 40min at 400 gwith no brake.
PBMCs were then removed and diluted 1:1 with sterile PBS. Cells were
then centrifuged at 350 g for 4 min and supernatant removed. PBMCs
were either used immediately or cultured in RPMI 1640 supplemented
with 5% fetal calf serum (FCS) (PromoCell, Heidelberg, Germany), 0.5%
L-glutamine (Sigma-Aldrich, United Kingdom), and 0.05 mg/ml strepto-
mycin and 50 U/ml penicillin (Sigma-Aldrich, United Kingdom) at 37°C
with 5% CO2.
PBMCs were centrifuged at 350  g for 4 min. The supernatant was
removed before washing with sterile PBS. Using the CD4 T cell isolation
kit II (Miltenyi Biotec, Surrey, United Kingdom), cells were then stained
with magnetic labels as per the manufacturer’s instructions. After mag-
netic labeling, the cells were then put through the LS columns (Miltenyi
Biotec, Surrey, United Kingdom) as per the manufacturer’s instructions.
CD4-positive lymphocyte activation assay. Stable keratinocyte cell
lines were stimulated with IFN- (10 ng/ml) and incubated for 8 h before
the cells were washed thoroughly to remove input IFN- and replaced
with freshmedium. Cells were incubated for a further 16 h before harvest-
ing. Isolated CD4-positive lymphocytes were stimulated with activating
anti-CD3/CD28 (150/200 ng/ml) antibodies and costimulated with IL-18
(20 ng/ml) in the presence of medium taken from keratinocyte cultures.
CD4-positive lymphocytes were incubated for 24 h before medium was
harvested and analyzed by enzyme-linked immunosorbent assay (ELISA)
for secreted IFN- production. Keratinocyte medium was analyzed in
parallel to confirm the absence of input IFN-.
RNA extraction and qRT-PCR. RNA was extracted from keratino-
cytes using the Quick-RNA MiniPrep (Zymo Research, Cambridge Bio-
science, Cambridge, UnitedKingdom) and cDNAgeneratedwith a cDNA
synthesis kit (Fermentas). Reverse transcription-quantitative PCR (qRT-
PCR) was performed on a RotorGen (Qiagen, Hilden, Germany) using a
		CT-analysis based on the generation of standard curves for both the
housekeeping gene (U6snRNA) and the target gene (IL-18BP) (Quanti-
Tect primer assay; Qiagen) using QuantiFast SYBR green PCR (Qiagen).
Lestaurtinib inhibitor assay.HPV18-containing keratinocytes grown
on mitomycin C-treated J2 3T3 and primary keratinocytes were treated
with 100 nM lestaurtinib (Tocris Biosciences) for 1 h at 37°C prior to
stimulationwith 10 ng/ml IFN- (BioLegend) for 24 h. Supernatants were
collected for ELISA, and cells were lysed for protein analysis.
Determination of IL-18BP and IFN- levels by ELISA.Quantities of
cytokines in cell-free supernatants were determined using the R&D Sys-
tems ELISA kit according to manufacturer’s instructions.
SDS-PAGE and immunoblotting. Cells were lysed in Leeds lysis buf-
fer supplemented with protease inhibitor cocktail (Roche) (23). Proteins
were separated by SDS-PAGE before transfer onto nitrocellulose mem-
brane (HyBond C Extra; Amersham Biosciences). Membranes were
probed with primary antibodies against 16E7 (Santa Cruz) and 18E7,
GAPDH (glyceraldehyde-3-phosphate dehydrogenase), and pRb (Ab-
cam) and horseradish peroxidase (HRP)-conjugated secondary antibod-
ies (Sigma). Proteins were detected using enhanced chemiluminescence
reagent.
Reporter gene assays.Dual-luciferase reporter assays were performed
as previously described (24). Keratinocytes were seeded at 3 105 cells/ml
in 24-well dishes prior to transfection. Cells were transfected with wild-
type andmutant IL-18BP promoter-driven firefly luciferase reporters and
a Renilla luciferase (RLTK)-expressing plasmid as a transfection control
using FuGene reagent. At 24 h posttransfection, cells were stimulatedwith
IFN- (BioLegend) for 12 h prior to lysis in passive lysis buffer (Promega).
Firefly luciferase levels were normalized to Renilla levels, and fold induc-
tion values were calculated relative to the normalized activity of the mock
control.
RESULTS
HPV16 E7 augments IL-18BP expression in primary keratino-
cytes. To gain insight into a possible effect of HPV oncoproteins
on endogenous IL-18BP secretion, primary human foreskin kera-
tinocytes were transduced with retroviruses expressing HPV16 E6
and E7 in isolation or E6/E7 from a bicistronic transcript. Viral
gene expression was confirmed by RT-PCR (data not shown).
Cells were stimulated with IFN-, a potent inducer of IL-18BP
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(25), for 16 h and culture supernatants analyzed by ELISA. In
control keratinocytes, expressing empty pBabe-Puro plasmid,
IFN- induced the secretion of IL-18BP (Fig. 1A). Expression of
16E6 induced amodest, but statistically significant, increase in the
levels of IL-18BP secretion, whereas 16E7 had the most pro-
nounced effect on IL-18BP secretion, inducing more than a dou-
bling in concentrations of cytokine compared with the control.
This was not significantly further increased in the presence of E6.
These data demonstrate that HPV oncoproteins, in particular E7,
enhance the levels of IL-18BP secreted from primary keratino-
cytes.
E7 proteins from other HPV types enhance IL-18BP ex-
pression. This is the first report to demonstrate that HPV16 E7
enhances IL-18BP expression. To establish whether enhanced
IL-18BP production was a general feature of E7 proteins, kera-
tinocytes stably expressing E7 proteins from severalmucosal types
were treated with IFN- and levels of IL-18BPmeasured by ELISA
(Fig. 1B). E7 from both low-risk (HPV6b and HPV11) and high-
risk (HPV16 andHPV18) types increased expression of IL-18BP to
comparable levels.These experiments illustrate that IL-18BP is a con-
served target for E7 proteins of multiple HPV types, suggesting that
increased IL-18BP levels may be necessary during the HPV life cycle
rather than associated directly with transformation.
The CR3 region of E7 is necessary for enhanced IL-18BP ex-
pression. Next, the regions of E7 important for enhancing IL-
18BP production were identified. Primary keratinocytes were
transduced with retroviruses expressing a panel of E7 proteins
containing mutations in the amino-terminal disordered con-
served region 1 (CR1) and CR2 or in the more structured carbox-
yl-terminal CR3 (25–29). Figure 2A shows a schematic diagram of
E7 and themutations examined in this study. E7 proteins contain-
ing single-amino-acid mutations in CR1 or CR2 (CR1-H2P or
CR2-C24G) retained the ability to increase IL-18BP production
upon IFN- treatment (Fig. 2B). Severalmutants containing small
FIG 1 E7 proteins augment IL-18BP expression in primary keratinocytes. (A)
Primary human foreskin keratinocytes stably expressing vector alone (pBabe-
Puro), HPV16 E7, HPV16 E6, or HPV16 E6sE7 were treated with IFN- (10
ng/ml) for 16 h. Following treatment, supernatants were harvested and levels
of secreted IL-18BP measured by ELISA. (B) Primary human foreskin kerati-
nocytes expressing E7 fromHPV6b, HPV11, HPV16, andHPV18were treated
with IFN- (10 ng/ml) for 16 h. Following treatment, supernatants were har-
vested and levels of secreted IL-18BP measured by ELISA. Results are ex-
pressed as the means 
 standard deviations (SD) from three independent
experiments. *, P 0.05; **, P 0.01.
FIG 2 Enhanced IL-18BP expression requires amino acids in the carboxyl terminus of E7. (A) Schematic of E7 and the mutations used in this study. Functional
regions of E7 are highlighted. Substitutions are shown, and small deletions are indicated by “	”. (B) Amino acids in CR3 are necessary for increased IL-18BP
production. Primary human foreskin keratinocytes stably expressing empty plasmid (pBabe), 16E7, 16E7 H2P, 16E7 C24G, and four carboxyl-terminal
truncations designated	1 (with deletion of amino acids 52 to 56),	2 (with deletion of amino acids 65 to 67),	3 (with deletion of amino acids 75 to 77), and	4
(with deletion of amino acids 79 to 83) were treated with IFN- (10 ng/ml) for 16 h. Following treatment, supernatants were harvested and levels of secreted
IL-18BP measured by ELISA. Results are expressed as the means 
 SD from four independent experiments. (C) Media and cell lysates from representative
experiments were subjected to SDS-PAGE and probed with the indicated antibodies to confirm E7 expression and test functionality of the mutations. GAPDH
was used to demonstrate equal loading of lysates.
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deletions in CR3 of E7 were also tested for their ability to augment
IL-18BP production. Keratinocytes stably expressing	1 (with de-
letion of amino acids 52 to 56) and 	4 (with deletion of amino
acids 79 to 83) showed IL-18BP levels similar to those in cells
expressing wild-type E7 (Fig. 2B). In contrast, cells expressing 	2
(with deletion of amino acids 65 to 67) and 	3 (with deletion of
amino acids 75 to 77) produced lower levels of IL-18BP, similar to
thosewith vector (pBabe-Puro) alone.While these data imply that
amino acids within 	2 and 	3 are necessary for the increased
IL-18BP production, it is plausible that the mutations may have
had additional impacts on E7 structure, sinceCR3 has been shown
to be highly structured (30, 31). To explore whether the panel of
mutants used in this studywere broadly functional, we tested their
expression level and ability to downregulate the cellular Rb pro-
tein, a key target for E7 proteins (28). Stable expression of the
mutant proteins was observed (Fig. 2C), although levels of C24G
were reduced compared with those of the wild type. Interestingly,
this mutant was still capable of increasing IL-18BP levels, suggest-
ing that only low levels of E7 are necessary for this function. Al-
though E7 has been reported to be secreted into the cell medium
and to bind directly to the IL-18 receptor (32), we could not detect
E7 in the media of our stable keratinocyte cell lines. As such, it is
unlikely that any secreted form of E7 was necessary for the ob-
served effects on IL-18BP (Fig. 2C).
As previously reported, expression of wild-type E7 reduced Rb
levels, while mutations in CR1 (H2P) or CR2 (C24G) abrogated
this ability and resulted in Rb levels similar to those for the vector
alone (Fig. 2C). Expression of the CR3 deletions reduced Rb levels
equivalently to the wild type, despite any small differences in E7
expression between samples. These data suggest that amino acids
within CR3 are required for increased IL-18BP and that the loss of
IL-18BP expression seen in the 	2 and 	3 mutant cell lines is not
due to gross changes in E7 structure.
Enhanced IL-18BP expression requires a proximal gamma-
activated sequence (GAS) element in the IL-18BP promoter. To
address whether the increased levels of IL-18BP protein were due
to increased mRNA abundance, time course experiments were
performed and levels ofmRNAexpression determined over a 24-h
time period of IFN- treatment using quantitative RT-PCR. IL-
18BP transcript was detectable at the 6-h time point in both con-
trol and E7-expressing keratinocytes, although transcript levels
were significantly greater in those expressing E7 (Fig. 3A). Tran-
FIG 3 E7-dependent IL-18BP transcription is mediated by a proximal GAS element in the IL-18BP promoter. (A) Primary human foreskin keratinocytes stably
expressing empty plasmid (pBabe) or 16E7 were treated with IFN- (10 ng/ml). RNA was extracted over a 24-h time course and analyzed by qRT-PCR for
IL-18BP and U6snRNA expression. Expression levels are shown as the fold IL-18BP mRNA increase compared to untreated controls. (B) As for panel A except
that supernatants were taken for measurement of secreted IL-18BP protein by ELISA. (C) Primary foreskin keratinocytes were transfected with the indicated
IL-18BP promoter reporter plasmids. After 24 h, cells were untreated or stimulated with IFN- (10 ng/ml) for 12 h and activity measured using a dual-luciferase
system. Results are expressed as the means 
 SD from four independent experiments. (D) Primary normal human foreskin keratinocytes (NHK) and kerati-
nocytes stably harboring the HPV18 genome were treated with IFN- (10 ng/ml) in the presence of DMSO (mock) or lestaurtinib (Lest) (100 nM), a
small-molecule inhibitor of the Jak-STAT signaling pathway, for 24 h and supernatants taken formeasurement of secreted IL-18BP protein by ELISA. Results are
expressed as the means
 SD from three independent experiments. **, P 0.01. Western blot analysis from representative samples of lysates taken from these
cells demonstrated that treatment with lestaurtinib did not reduce E7 expression. GAPDH was used as a protein loading control.
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script levels continued to increase until the 24-h time point and
were greater in all samples containing E7. This trend was also
observed with secreted IL-18BP (Fig. 3B). Despite a delay in pro-
tein production until 24 h in the control cells, secreted IL-18BP
was detectable at as early as 12 h in cells expressing E7 (Fig. 3B).
IL-18BP transcription is thought to be dependent on the gam-
ma-activated sequence (GAS) within the IL-18BP promoter ele-
ment, which can be bound by members of the signal transducer
and activator of transcription (STAT) family of transcription fac-
tors (33). The IL-18BP promoter element contains two conserved
GASs, one directly adjacent to the transcriptional start site (bp
25 to33) and a second, more distal site, located at bp625 to
633 (21). To begin to decipher the signaling pathways leading to
IL-18BP production in E7-expressing cells, luciferase reporter as-
says were performed. Control and E7-expressing keratinocytes
were transfectedwith a reporter plasmid driving luciferase expres-
sion from the IL-18BP promoter (pGL3-BP WT) (Fig. 3C). In
addition, three further reporter plasmids were used. These con-
structs contained mutations that inactivated either the proximal
(pGL3-BP prox), distal (pGL3-BP dist), or both (pGL3-BP dist/
prox) (21) GASs. Treatment with IFN- induced luciferase ex-
pression from the wild-type IL-18BP promoter reporter (Fig. 3C).
Mutation of the proximal, but not the distal, GAS in the promoter
significantly reduced luciferase production in response to IFN-
treatment in both control and E7-expressing cells. Importantly,
the double mutation at the proximal and distal GASs was not
associated with any further suppression of luciferase expression
compared to that with the single proximal mutant. These results
indicate that E7 expression modulates IL-18BP production
through the canonical proximal GAS.
It was important to examine the effects of E7 on IL-18BP pro-
duction in the context of the complete HPV genome in which all
viral factors are present. For this, primary human keratinocytes
harboring the HPV18 genome were generated using published
protocols (22). Control or HPV18-harboring keratinocytes were
incubated with dimethyl sulfoxide (DMSO) (mock) or the small-
molecule Jak kinase inhibitor lestaurtinib (100 nM) (34) for 1 h
prior to stimulation with IFN-. As seen in Fig. 3D, levels of IL-
18BP were significantly reduced in the media of both control and
HPV18-containing keratinocytes. Treatment did not significantly
alter levels of the E7 protein, suggesting that abrogation of Jak
signaling prevents E7-mediated production of IL-18BP. Overall,
these data strongly suggest that IL-18BP production requires a
functional Jak-STAT signaling pathway in E7-expressing cells.
The enhanced IL-18BP expression by E7 reduces activation
of primary CD4-positive lymphocytes. The cellular immune re-
sponse is essential for destruction of HPV-infected keratinocytes.
IL-18 is known to augment this by increasing IFN- secretion
from activated T lymphocytes (16). As IL-18BP antagonizes the
effects of IL-18, wewanted to assess the biological consequences of
increased IL-18BP production by E7-expressing keratinocytes.
Primary human CD4-positive T lymphocytes were isolated from
the PBMCs of healthy volunteers and stimulated with anti-CD3/
CD28 antibodies. Activated lymphocytes were subsequently incu-
bated with IL-18 in the presence of medium taken from keratino-
cytes stably expressing vector alone, wild-type E7, or 	2 E7 and
analyzed after 24 h for IFN- secretion by ELISA. As shown in Fig.
4, exposure to media from all keratinocytes caused a reduction in
IFN- release from the CD4-positive lymphocytes. This was to be
expected since themedia contained various levels of IL-18BP. Im-
portantly, exposure tomedium from the wild-type-E7-expressing
keratinocytes resulted in the most pronounced inhibition of
IFN- production. To confirm that increased IL-18BP produc-
tion was necessary for the reduced IFN- levels produced by the
CD4-positive lymphocytes, we assessed the effects of the	2 E7 cell
line on IFN- production. CD4-positive lymphocytes incubated
inmedium from the	2 cell line producedmore IFN- than those
from the wild-type E7 cell line, with levels resembling those with
the vector alone. To preclude the possibility that IFN- was pres-
ent in the input samples, we tested both the mock samples and
keratinocyte medium. These samples contained undetectable lev-
els of IFN-. Overall, these data suggest that the increased levels of
IL-18BP produced by E7-expressing keratinocytes have an inhib-
itory effect on CD4-positive lymphocytes.
DISCUSSION
The pathogenesis of HPV infection is directly linked to the im-
mune responses of the host, which depend on the secretion of
specific cytokines to attract components of the adaptive immune
system to the site of virus infection. However, HPV infections
appear to be immunologically deficient and suffer from reduced
inflammatory infiltrate (34). Several mechanisms have been pro-
posed to explain the observed immunodeficiency, and these focus
mainly on the E6 and E7 oncoproteins. Both E6 and E7 have been
shown to target the IL-18 receptor directly, to prevent activation
of target cells (32). E6 and E7 also prevent the transcription of
inflammatory cytokines by targeting antiviral signaling pathways
(9, 14, 35).
Our data provide the first evidence for upregulation of IL-18BP
by a virus protein in the context of both overexpression of the
individual protein and the stable expression of the entire HPV
genome. Given the critical role of IL-18 in the skin inflammatory
response to virus infection, which includes increasing the expres-
sion of antiviralmolecules such asMHC-II (17), it is likely that the
FIG 4 Effect of increased IL-18BP expression on IL-18-induced IFN- pro-
duction in primary human CD4 lymphocytes. Primary human foreskin kera-
tinocytes stably expressing empty plasmid (pBabe), HPV16 E7, or HPV16 	2
E7 were treated with IFN- (10 ng/ml) for 8 h. Cells were washed to remove
input IFN- and treated with fresh medium for a further 16 h. Keratinocyte
supernatants were collected and added to cultures of anti-CD3/CD28-acti-
vated human CD4 lymphocytes, which were costimulated with IL-18 (20 ng/
ml) for 24 h. Supernatants were harvested and levels of secreted IFN- mea-
sured by ELISA. Mock-treated cells and keratinocyte supernatant alone were
used as controls to demonstrate absence of IFN- from input samples. The
data represent the average from five independent experiments, and error bars
indicate SD. *, P 0.05.
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suppressive effects associated with increased IL-18BP present in
the vicinity of HPV infection would lead to a diminished cellular
immune response associated with HPV infection. The results of
this study demonstrate that medium produced from E7-express-
ing keratinocytes is able to inhibit primary CD4-positive lympho-
cytes costimulated with IL-18. Importantly, the E7 	2 mutant,
which was unable to increase the expression of IL-18BP from ke-
ratinocytes, was also not able to inhibit IFN- production from
the CD4-positive lymphocytes, suggesting that IL-18BP is neces-
sary for the effects seen in this assay. Despite this, the use of neu-
tralization assays with IL-18BP-specific antibodies would greatly
strengthen these findings.
Interestingly, E7 proteins from low-risk HPV6b and -11 were
also capable of increasing IL-18BP expression, suggesting that IL-
18BP is an important target for E7 and may contribute to HPV
persistence in infected individuals. Mapping studies identified
residues in the carboxyl CR3 region of E7 necessary for the in-
creased IL-18BP production. This region contributes to a number
of E7 functions, including dimerization (36). It may also mediate
interactions with a number of cellular proteins, including cullin 2,
HDAC, pCAF, p300, TATA binding protein, and Rb (25, 27, 29,
37, 38). The interaction of E7 with one or several of these proteins
may be important for regulating IL-18BP production.
IL-18BP expression is mediated by a number of response ele-
ments found within the IL-18BP promoter, and a proximal GAS
element is necessary for IFN--mediated expression (21). Mem-
bers of the STAT family of transcription factors bind GAS ele-
ments, and HPV proteins have been shown to differentially regu-
late these proteins during the virus life cycle (39–42), which may
help to coordinate the pleiotropic effects observed on the immune
system. The time course experiments demonstrated earlier kinet-
ics of IL-18BP expression in E7-expressing cells than in controls.
This is unlikely due to different signaling pathways and so may
indicate that E7 also functions through an as-yet-unidentified
pathway or acts on a novel negative regulatory protein that func-
tions to suppress IL-18BP expression.
In conclusion, our results add HPV to the short list of persis-
tent viruses that are currently known to modulate the IL-18-IL-
18BP axis. Given the critical nature of IL-18 for mounting the
defensive response to virus infection, we propose that IL-18BP is
likely to be targeted by a growing number of viruses.
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